research Characterization of Novel TMEM173 Mutation with Additive IFIH1 Risk Allele
A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
Search
forLearn
0 / 0 results — no results
Research
5 / 1000+ results 
research Nanocarrier-Based Approaches for Enhanced Management of Androgenetic Alopecia: Advancements and Future Prospects
Nanocarriers could improve hair loss treatments by delivering drugs directly to hair follicles.
research 17β-Estradiol Enhances Vascular Endothelial Growth Factor Production and Dihydrotestosterone Antagonizes the Enhancement via the Regulation of Adenylate Cyclase in Differentiated THP-1 Cells
Estrogen increases blood vessel growth factor production, while testosterone blocks this increase.
research Expression of Hypothalamic-Pituitary-Thyroid Axis Related Genes in Human Skin
Thyroid-related genes are active in skin cells and may affect autoimmune conditions.
research Regulation of Somatic Cell Reprogramming Through Inducible miR-302 Expression
Increasing mir-302 turns human hair cells into stem cells by changing gene regulation and demethylation.
Community Join
5 / 65 resultscommunity Amplifica AMP-303 study results are expected late this summer
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
community Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.